Yamada Akira, Oguchi Kazuhiro, Fukushima Mana, Imai Yutaka, Kadoya Masumi
Department of Radiology, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto, Nagano 390-8621, Japan.
Ann Nucl Med. 2006 Nov;20(9):597-604. doi: 10.1007/BF02984657.
Variable uptake of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has been noticed in positron emission tomography (PET) studies of gastric carcinoma patients, with low uptake occurring especially in some particular histological subtypes and early carcinomas. But this phenomenon has not been adequately explained. The aim of the present study is to clarify FDG uptake in gastric carcinomas especially focusing on histological subtypes, the depth of tumor invasion, and glucose transporter-1 (GLUT-1) expression which is considered to be one of the major factors for higher FDG uptake in human malignant tumors.
FDG-PET was performed on 35 preoperative patients with gastric carcinoma. Forty macroscopically distinguishable lesions on a surgical specimen were histologically classified into two subtypes: Cohesive type (papillary adenocarcinoma, tubular adenocarcinoma, and solid type poorly differentiated adenocarcinoma) or Noncohesive type (signet-ring cell carcinoma and non-solid type poorly differentiated carcinoma). GLUT-1 expression was immunohistochemically determined. Histological parameters (GLUT-1 expression, histological subtypes, the depth of invasion, lymphatic permeation, venous invasion and tumor size) were evaluated, and factors for FDG uptake (detectability and the degree) and GLUT-1 overexpression were determined by multiple regression analysis.
Nineteen of 40 gastric carcinomas showed detectable FDG uptake (48%), multiple regression analysis revealed that both the depth of invasion and histological subtypes are independent factors that influence the detectable FDG uptake in gastric carcinoma (R2 = 0.66). GLUT-1 expression was seen from an early cancer stage and the cohesive type was an independent factor influencing the overexpression of GLUT-1 (R2 = 0.66). GLUT-1 expression was the most influential factor for the degree of FDG uptake in gastric carcinoma (R2 = 0.68).
This study provided important information on the clinical application of FDG-PET in gastric carcinoma that early or non-cohesive gastric carcinoma may show lower FDG uptake. Therefore, the usefulness of FDG-PET for the detection of gastric carcinoma is limited. But there is a possibility that FDG uptake associated with GLUT-1 expression may serve as a prognostic factor of gastric carcinoma representing tumor metabolism.
在胃癌患者的正电子发射断层扫描(PET)研究中,已注意到2-脱氧-2-[18F]氟-D-葡萄糖(FDG)摄取存在差异,低摄取尤其发生在某些特定组织学亚型和早期癌中。但这一现象尚未得到充分解释。本研究的目的是阐明胃癌中的FDG摄取情况,尤其关注组织学亚型、肿瘤浸润深度以及葡萄糖转运蛋白-1(GLUT-1)表达,GLUT-1表达被认为是人类恶性肿瘤中FDG摄取增加的主要因素之一。
对35例术前胃癌患者进行FDG-PET检查。手术标本上40个肉眼可区分的病变在组织学上分为两个亚型:凝聚型(乳头状腺癌、管状腺癌和实体型低分化腺癌)或非凝聚型(印戒细胞癌和非实体型低分化癌)。采用免疫组织化学方法测定GLUT-1表达。评估组织学参数(GLUT-1表达、组织学亚型、浸润深度、淋巴浸润、静脉浸润和肿瘤大小),并通过多元回归分析确定FDG摄取(可检测性和程度)及GLUT-1过表达的相关因素。
40例胃癌中有19例显示可检测到的FDG摄取(48%),多元回归分析显示浸润深度和组织学亚型都是影响胃癌中FDG可检测摄取的独立因素(R2 = 0.66)。GLUT-1表达在癌症早期即可出现,凝聚型是影响GLUT-1过表达的独立因素(R2 = 0.66)。GLUT-1表达是胃癌中FDG摄取程度的最有影响因素(R2 = 0.68)。
本研究为FDG-PET在胃癌中的临床应用提供了重要信息,即早期或非凝聚型胃癌可能显示较低的FDG摄取。因此,FDG-PET用于检测胃癌的效用有限。但与GLUT-1表达相关的FDG摄取有可能作为代表肿瘤代谢的胃癌预后因素。